Novartis and 111 Inc. Collaborate to Explore Innovative Disease Management Model for Psoriasis

Shanghai, September 25, 2020 /PRNewswire/ -- On September 24, 2020, the 3rd China Internet Healthcare Summit, hosted by 1 Drug Network (Yi Yao Wang), was grandly held in Shanghai. Themed "Digital Connectivity · Technology for All," the summit brought together numerous industry elites, including pharmaceutical executives and leading investors. During the summit, Novartis China (hereinafter referred to as "Novartis") and 1 Drug Network jointly announced the "Silver Future – Psoriasis Disease Management" project, aiming to actively explore new models of collaboration in the "Internet + Psoriasis" field. Ms. Zhang Ying, President of Novartis China, and Dr. Yu Gang, Co-founder and Executive Chairman of 1 Drug Network, among other distinguished guests, attended the launch ceremony.

1. 1Drug.com will provide psoriasis patients with a one-stop “medical + pharmaceutical” service. Meanwhile, both parties will explore leveraging Novartis’ expertise in innovative psoriasis medications to better serve patients. Furthermore, by utilizing 1Drug.com’s nationwide intelligent supply chain network, the accessibility of innovative psoriasis drugs will be significantly enhanced, enabling patients to receive home delivery and personalized services from the comfort of their homes.

On this occasion, 1 Drug Network also plans to invite Novartis to jointly explore new models of disease management in the field of “Internet + Psoriasis.” By leveraging digital technologies such as internet technology, big data, cloud service solutions, and intelligent supply chains, the company aims to further optimize patients’ disease management processes. Through systematic CRM management, it seeks to enhance medication adherence among psoriasis patients, improve their medication experience and self-management awareness, and help more psoriasis patients gain a correct understanding of the disease.

Amid the current imbalance between the supply and demand of medical resources, the collaborative projects being explored by both parties will help achieve dynamic connectivity between patients and physicians outside hospital settings. This initiative aims to improve access to diagnosis and treatment for psoriasis patients, alleviate physicians’ workload, enhance work efficiency, and promote the efficient and rational utilization of medical resources.

Ms. Zhang Ying, President of Novartis China, stated that the pandemic has further accelerated the development of the internet-based pharmaceutical and healthcare industry. The internet not only enhances drug accessibility but also provides great convenience for patients to access medical services. Novartis boasts profound expertise in innovative drug R&D and disease research, while 1YaoWang has established strong advantages in online medical services, big data, and intelligent supply chain management.

Psoriasis has been listed by the World Health Organization as one of the top ten intractable diseases of the 21st century. It is an immune-mediated, chronic, relapsing, inflammatory, and systemic disease. Psoriasis follows a prolonged course with a predisposition to recurrence, and some cases remain incurable throughout the patient’s lifetime. Currently, there are approximately 125 million psoriasis patients worldwide, with about 6.5 million in China. Due to patients’ lack of scientific awareness regarding disease management, how to help patients achieve whole-course disease management and implement long-term follow-up has become an urgent challenge for the industry to address.

Dr. Yu Gang, Co-founder and Executive Chairman of 1 Drug Network (1 Yao Wang), stated that the difficulties in accessing medical care and purchasing medications have long been pain points for patients in China. The mission of 1 Drug Network is to leverage digital technology to organically connect patients with pharmaceuticals and healthcare services. This collaborative exploration with Novartis in the field of “Internet + Psoriasis” not only meets patient needs but also aligns with the future development trends of the industry. We look forward to both parties fully leveraging their respective resources and advantages to continue exploring more efficient disease management models for psoriasis, safeguarding the health and lives of more patients, benefiting a broader patient population, and contributing to the realization of the “Healthy China 2030” initiative.